secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001808805-23-000073
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Biotechnology Q3 net loss $15.9M, op ex up 21% YoY to $19.1M
---------------------------------------------------------------------

- Net loss of $15.9M for Q3 2023 vs. $14.1M in Q3 2022.
- Operating expenses rose 21% YoY to $19.1M, driven by increased headcount for product development.
- Cash, cash equivalents and investments totaled $275.7M as of Sept. 30, 2023.
- Company reiterates focus on commercial platform launch in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880523000073/0001808805-23-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880523000073/naut-20231031.htm
  HTML page:      https://secwatch.observer/filing/0001808805-23-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer